Fatty liver disease (MASLD/MASH) trials in China

In China 73 Also abroad 367

73 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
Where
Bengbu, Guangzhou, Haikou, Hangzhou, Hefei, Hengyang, Kunming, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Weifang, Wenzhou, Wuhan, Wuhu, Xi’an, Xuzhou, Zhengzhou, Zunyi
Age
18 years and over
People
10,000
Run by
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07632677
No phaseTaking people
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
Where
Beijing
People
2,000
Run by
Peking Union Medical College Hospital
See details and how to joinNCT05330923
Phase 2Taking people
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Where
Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shiyan, Tianjin, Ürümqi, Wuhan, Xi’an
Age
18 years to 75 years
People
300
Run by
Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07303803
No phaseTaking people
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
Where
Hangzhou
Age
65 years to 100 years
People
20,000
Run by
The Affiliated Hospital of Hangzhou Normal University
See details and how to joinNCT07241195
No phaseNot yet taking people in China
Integrated Ultrasound-Derived Fat Fraction and 2D/4D HeartAI for Cardiovascular Risk Management in Patients With MASLD
Where
Guangzhou
Age
18 years to 75 years
People
700
Run by
First Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT07545343
No phaseTaking people
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
Where
Guangzhou
People
240
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07265544
Phase 4Taking people
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Where
Jiangxi
Age
18 years to 75 years
People
100
Run by
Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07272343
Phase 2Taking people
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Where
Shenzhen
Age
18 years to 75 years
People
120
Run by
Hudson Biotech
See details and how to joinNCT07481734
No phaseTaking people
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
Where
Shanghai
Age
18 years to 70 years
People
100
Run by
Shanghai East Hospital
See details and how to joinNCT07463287
No phaseNot yet taking people in China
An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease
Where
Guangzhou
Age
18 years and over
People
200
Run by
Zhujiang Hospital
See details and how to joinNCT07455149
Early phase 1Not yet taking people in China
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
Where
Jilin City
Age
18 years to 65 years
People
94
Run by
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
See details and how to joinNCT07407634
Early phase 1Taking people
Efficacy and Safety of Rifaximin-α in Treating MASLD
Where
Shanghai
Age
18 years to 75 years
People
60
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07381257
Phase 2Taking people
A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
Where
Beijing, Chengdu
Age
18 years to 65 years
People
80
Run by
Hinova Pharmaceuticals Inc.
See details and how to joinNCT07308548
Phase 2/3Taking people
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Where
Shanghai
Age
18 years and over
People
20
Run by
Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07285850
Early phase 1Taking people
Efficacy and Safety of Rifaximin in Treating MAFLD
Where
Shanghai
Age
18 years to 75 years
People
40
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07185932
No phaseNot yet taking people in China
CPET-based HIIT for MAFLD
Where
Beijing
Age
35 years to 65 years
People
54
Run by
Tang Yida
See details and how to joinNCT07177963
No phaseTaking people
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
Where
Wuhan
People
500
Run by
Tongji Hospital
See details and how to joinNCT07149571
Phase 1Taking people
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
Where
Beijing, Datong, Guangzhou, Tianjin, Wenzhou
Age
18 years to 75 years
People
32
Run by
Tasly Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07128797
No phaseTaking people
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease
Where
Changsha, Yichang
Age
18 years to 75 years
People
120
Run by
State Key Laboratory of Subhealth Intervention Technology
See details and how to joinNCT05439226
No phaseNot yet taking people in China
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Where
Wuhan
Age
18 years to 75 years
People
40
Run by
Huazhong University of Science and Technology
See details and how to joinNCT07085962
No phaseNot yet taking people in China
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
Where
Beijing, Changsha, Changzhi, Foshan, Fuzhou, Guangzhou, Guiyang, Jincheng, Jinzhong, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shiyan, Taiyuan, Zhuhai
Age
18 years to 75 years
People
735
Run by
Beijing Friendship Hospital
See details and how to joinNCT07087041
No phaseNot yet taking people in China
Prognostic Model for MASLD Related Cirrhosis
Where
Beijing, Tianjin
Age
18 years to 80 years
People
228
Run by
Beijing Friendship Hospital
See details and how to joinNCT07082751
No phaseTaking people
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
Where
Changsha, Yichang
Age
18 years and over
People
120
Run by
State Key Laboratory of Subhealth Intervention Technology
See details and how to joinNCT07083336
Phase 1/2Not yet taking people in China
To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH
Where
Changchun
Age
18 years to 65 years
People
40
Run by
Changchun Intellicrown Pharmaceutical Co. LTD
See details and how to joinNCT07016633
No phaseTaking people
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Where
Ningbo
Age
20 years to 90 years
People
2,720
Run by
Ningbo No. 1 Hospital
See details and how to joinNCT06984510